DrugPatentWatch Database Preview
Indivior Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for INDIVIOR INC, and what generic alternatives to INDIVIOR INC drugs are available?
INDIVIOR INC has six approved drugs.
There are twenty-three US patents protecting INDIVIOR INC drugs.
There are two hundred and fifty-three patent family members on INDIVIOR INC drugs in thirty-five countries and one supplementary protection certificate in one country.
Summary for Indivior Inc
| International Patents: | 253 |
| US Patents: | 23 |
| Tradenames: | 5 |
| Ingredients: | 4 |
| NDAs: | 6 |
| Patent Litigation for Indivior Inc: | See patent lawsuits for Indivior Inc |
Drugs and US Patents for Indivior Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indivior Inc | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | 8,975,270 | Start Trial | Y | Start Trial | |||
| Indivior Inc | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-002 | Nov 30, 2017 | RX | Yes | Yes | 9,498,432 | Start Trial | Y | Start Trial | |||
| Indivior Inc | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-001 | Jul 27, 2018 | RX | Yes | No | 9,180,197 | Start Trial | Y | Start Trial | |||
| Indivior Inc | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-004 | Aug 10, 2012 | AB | RX | Yes | Yes | 8,475,832 | Start Trial | Y | Start Trial | ||
| Indivior Inc | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-004 | Aug 10, 2012 | AB | RX | Yes | Yes | 9,931,305 | Start Trial | Y | Start Trial | ||
| Indivior Inc | PERSERIS KIT | risperidone | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 210655-002 | Jul 27, 2018 | RX | Yes | Yes | 9,180,197 | Start Trial | Y | Start Trial | |||
| Indivior Inc | SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819-001 | Nov 30, 2017 | RX | Yes | No | 9,498,432 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for INDIVIOR INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Sublingual Film | 2 mg/0.5 mg and 8 mg/2 mg | ➤ Subscribe | 2012-10-15 |
| ➤ Subscribe | Sulingual Film | 12 mg/3 mg | ➤ Subscribe | 2014-03-26 |
| ➤ Subscribe | Sublingual Film | 4 mg/1 mg | ➤ Subscribe | 2013-05-14 |
International Patents for Indivior Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 102481250 | Start Trial |
| Australia | 2008216887 | Start Trial |
| Japan | 2009518405 | Start Trial |
| Chile | 2012003462 | Start Trial |
| Canada | 2468557 | Start Trial |
| Japan | 2011093936 | Start Trial |
| European Patent Office | 1587504 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Indivior Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0196132 | 94C0008 | Belgium | Start Trial | PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
